AI Article Synopsis
- Women with late-stage ovarian cancer face high mortality rates, making early detection crucial for improving outcomes.
- Large-scale screening using blood biomarkers is essential, with current clinical focus primarily on cancer antigen 125 (CA125), despite its limitations.
- The text reviews recent advances in biosensor technology for detecting ovarian cancer biomarkers like CA125, HE4, and apolipoprotein A1, while also addressing the challenges and scarcity of biosensors for this disease.
Article Abstract
Women diagnosed with late-stage ovarian cancer suffer a very high rate of mortality. Accordingly, it is imperative to detect and diagnose the disease as early as possible in its development. Achievement of this aim implies relatively large-scale screening of women at an age of clinical significance through assay of biomarkers for disease present in blood or serum. Biosensor detection offers an attractive technology for the automated detection of such species. Among several biomarkers that have been identified that are present in patients with ovarian cancer, the only one that is commonly tested for in clinical use is cancer antigen 125, which is considered to be a poor biomarker for the disease. Here, we describe several biosensors that developed in the past decade for the detection of ovarian cancer biomarkers such as CA125, human epididymis protein 4 (HE4) and apolipoprotein A1. The challenges presented by the fabrication of biosensor devices for detecting ovarian cancer and the limited number of biosensors developed for this purpose are discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519542 | PMC |
| http://dx.doi.org/10.1002/ansa.202400029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!